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Abstract
Background: The placenta is an important site for iron metabolism in humans. It transfers iron
from the mother to the fetus. One of the major iron transport proteins is transferrin, which is a
blood plasma protein crucial for iron uptake. Its localization and expression may be one of the
markers to distinguish placental dysfunction.
Methods: In the experimental study we used antibody preparation, mass spectrometric analysis,
biochemical and immunocytochemical methods for characterization of transferrin expression on
the human choriocarcinoma cell line JAR (JAR cells), placental lysates, and cryostat sections. Newly
designed monoclonal antibody TRO-tf-01 to human transferrin was applied on human placentae
from normal (n = 3) and abnormal (n = 9) pregnancies.
Results: Variations of transferrin expression were detected in villous syncytiotrophoblast, which
is in direct contact with maternal blood. In placentae from normal pregnancies, the expression of
transferrin in the syncytium was significantly lower (p < 0.001) when compared to placentae from
abnormal ones (gestational diabetes, pregnancy induced hypertension, drug abuse).
Conclusion: These observations suggest that in the case of abnormal pregnancies, the fetus may
require higher levels of transferrin in order to prevent iron depletion due to the stress from the
placental dysfunction.

Background
All cells and organisms require iron to perform basic cellular processes. Its importance in respiration and oxygen
transport led to the evolution of an effective transport system of iron ions throughout the organism. This transport
is mediated by transferrin (TF), serum protein produced
especially by hepatocytes. Transferrin (TF; PRO2086) is a

glycoprotein with a molecular mass of 76–80 kDa carrying homologous C- and N- terminal iron-binding
domains [1]. Bound ferric iron ions are transported from
the intestine, reticuloendothelial system, and liver parenchymal cells through the blood to all proliferating cells in
the body. The process is based on receptor-mediated
endocytosis. After nonlysosomal (endosomal) dissocia-
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tion of iron, transferrin and its receptor return to the extracellular environment and the cell membrane, respectively
[2].
Aside from their essential synthesis in the liver, transferrins are also described to be produced locally in the testes
(Sertoli cells) and the central nervous system (brain glialcells, choroid plexus) [3], as well as in fetal membranes
and the placenta [4], which are areas relatively inaccessible to proteins in the general circulation. As all cells
require iron from serum transferrin produced by hepatocytes, cells that create the blood barrier of the testes, brain
and placenta tissue express the transferrin gene to provide
iron to cells sequestered within the serum-free environment [5]. As for embryo development, the growing fetus
needs increasing amounts of iron, which is provided by its
release from maternal transferrin. It is responsible for the
transport of iron to cells within both the fetal and maternal systems, but it does not cross the multiple cell layer
barrier of the placenta. Recent findings that human placental cells produce TF indicated that placental TF may be
involved in the transport or regulation of iron passage
across this barrier [6]. Iron deficiency anemia early in
pregnancy doubles the risk of preterm delivery [7], while
fetal anemia may contribute to the development of cardiovascular disease in adulthood [8]. Understanding how
iron is transported through the placenta is important in
this context. However, placental production of transferrin
still remains to be clarified [6].
In our laboratory, we prepared antibodies targeted against
selected placental proteins. The monoclonal antibody
designated TRO-tf-01 was shown to specifically recognize
one isoform of transferrin in the human placenta. This
paper describes the expression differences of this isoform
of transferrin in placental samples with respect to their
diverse physiological statuses. The evaluation of changes
in transferrin expression could help to understand the placental adaptive mechanisms involved in compensating
the function in abnormal pregnancies.

Methods
Sample collecting
Term placentae of three normal (NP) and nine abnormal
pregnancies of mothers admitted to the University of Tennessee Medical Center to deliver were examined by indirect peroxidase immunohistochemistry. Excluded were
patients with blood transferable infections, e.g., hepatitis
and HIV, and apparent ascendant placental infections.
The study was approved by the Institutional Review Board
and all patients signed the "Informed Consent". For the
study, some abnormalities of placentae were selected. A
group of abnormal pregnancies consisted of gestational
diabetes (GD, n = 3), pregnancy-induced hypertension
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(PIH, n = 3), and drug abuse (crack, cocaine) during pregnancy (DrA, n = 3).
Sample preparation, extraction
For biochemical analysis, samples of placental tissue were
treated as described elsewhere [9]. Human choriocarcinoma cell line (JAR cells) was cultivated in RPMI medium
(RPMI 1640, Sevapharma, Prague, Czech Republic) supplemented with 10% fetal bovine serum (FBS, Sigma,
Prague, Czech Republic) for three days. After their
removal with ethylenediaminetetraacetic acid (EDTA),
the cells were washed three times (centrifugation at 300 ×
g for 15 min at 25°C) in phosphate-buffered saline (PBS,
20 mM phosphate buffer, 0.15 M NaCl, pH 7.4). Suspension of washed cells was centrifuged at 1000 × g (10 min
at 4°C) and the pellet was resuspended in sodium
dodecyl sulfate (SDS) (twice concentrated non-reducing
SDS sample buffer) or by adding an ice-cold lysis buffer
(20 mM Tris pH 7.5, 0.20 M NaCl, 0.25% Nonidet P-40;
400 μl/100 mg of cell mass or placental tissue) containing
1 mM of sodium orthovanadate, 10 mM of sodium fluoride, and 1 mM of phenylmethylsulfonyl fluoride [9].
After heating in a boiling water bath for 3 min (SDS
extraction) or after 15 min on ice (Nonidet P-40 extraction), the lysates were sonicated using a SonicatorTM Cell
Disruptor (Heat Systems-Ultrasonic, Inc., Plainview, NY)
for 5 seconds, and centrifuged (at 15000 × g for 20 min at
4°C), and the aliquots of lysates were deep-frozen at 70°C. For Western blot analysis, protein concentrations
were determined by BCA Bradford assay (Bio-Rad, Hercules, CA).
Immunization and monoclonal antibody preparation
Monoclonal antibody TRO-tf-01 was prepared by the
immunization of BALB/c mice (Velaz, Prague, Czech
Republic) with JAR cells. Mice were twice subcutaneously
immunized within 10 days with 50 μg of total protein in
75 μl 1:1 crude extract: complete Freund adjuvant (CFA,
Sigma, Prague, Czech Republic). A booster injection of
150 μl 1:1 crude CFA extract was applied intraperitoneally
10 days after the second immunization. The volume was
equivalent to 100 μg of total protein. Three days after the
third immunization, hyperimmune spleen cells were
fused with myeloma cells Sp2/0. Positive clones were
selected by enzyme-linked immunosorbent assay (ELISA).
Standard protocols for hybridoma production, selection,
cloning and specificity controls were performed as
described before [10].
Monoclonal antibody isotyping kit
For the isotype characterization of the TRO-tf-01 monoclonal antibody, a mouse monoclonal antibody isotyping
kit (IsoStrip, Roche, Indianapolis, USA) was used according to the manufacturers instructions.
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Briefly, a supernatant of TRO-tf-01 antibody was diluted
in PBS (1:50). A freshly diluted sample (150 μl) was pipetted into a development tube, and agitated so that the
colored latex beads were completely resuspended. An isotyping strip was placed in the tube. Within 5 min, a blue
band appeared, indicating the class or subclass and lightchain composition of the monoclonal antibody.
Enzyme-linked immunosorbent assay (ELISA)
One hundred μl of individual JAR extracts diluted by
phosphate-buffered saline (PBS, 20 mM phosphate
buffer, 0.15 M NaCl, pH 7.4) to a concentration of 0.05 –
1.0 μg/μl were used for coating the wells of a 96-well
microplate (overnight at 4°C). After coating, the plate was
washed three times with PBST (PBS, 0.05% Tween 20),
and 100 μl bovine serum albumin – phosphate-buffered
saline-Tween (BSA-PBST) (PBS, 1% BSA, 0.05% Tween
20) were added for 1 hour at 25°C to block nonspecific
binding sites. After triple washing with PBST, 100 μl of
MoAb TRO-tf-01 supernatant, serially diluted in BSAPBST, were added to the appropriate wells and the plate
was incubated for 1 hour at 37°C. After the antibody-antigen reaction, the plate was washed three times with PBST,
and 100 μl (1.4 μg) of peroxidase-conjugated swine antimouse antibody (SWAM/Px, Sevapharma, Prague, Czech
Republic) were added to each well. The plate was then
incubated for 1 hour at 37°C. The reaction was stopped
by adding 4 N H2SO4. The peroxidase activity was
detected with a Sunrise Absorbance Reader (Tecan Trading AG, Switzerland) at 492 nm using H2O2 and o-phenylenediamine (Fluka, Buchs, Switzerland) after triple
washing with PBST.
SDS-PAGE and immunoblotting
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was performed according to the method
of Laemmli [11]. Equal amounts (20 μg) of boiled protein
(3 min at 100°C) were loaded onto reducing 10% SDSTris-glycine polyacrylamide gels. Electrophoresis proceeded in electrode buffer (0.25 M Tris, 1.92 M glycine,
10% SDS) at a constant amperage of 16 mA/gel. The
molecular mass of proteins banded in the gels was estimated using molecular weight markers (Sigma, Prague,
Czech Republic) run parallelly.

For immunodetection, the separated proteins were then
electrophoretically transferred onto Hybond C-super
nitrocellulose membranes (Amersham Biosciences, Uppsala, Sweden) according to the arrangement described by
Towbin et al. [12]. Electrophoretical transfer was carried
out in a Tris-glycine transfer buffer (pH 9.6) with 20% (v/
v) methanol in an LKB Transpher System at a starting
amperage of 0.5 mA/cm2 (2 h at 4°C).
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In 2-D electrophoresis experiments, isoelectric focusing
was performed according to the standard manufacturer's
protocol (Immobiline DryStrip Instruction manual, GE
Healthcare, Prague, Czech Republic). The total protein
lysate of the placental tissue (180 μg) was applied during
rehydratation of the 13 cm pH 4–7 Immobiline DryStrip
(Ettan IPGphor 3, GE Healthcare, Prague, Czech Republic). In the second dimension, 10% polycrylamide slab gel
(SDS) was used.
In immunodetection, the blocking of the membranes was
done overnight with 5% gelatin (Sigma, Prague, Czech
Republic) in PBST (PBS, 0.05% Tween 20) at 4°C. The
membranes were incubated with a supernatant of MoAb
TRO-tf-01 (1:200 dilution in 1% gelatin-PBST) at 25°C
for 1 hour. After five 5-minute washes in PBST, the membranes were incubated with horseradish peroxidase
(HRP)-conjugated goat anti-mouse antibody (GAM/Px)
(Bio-Rad, Prague, Czech Republic) diluted 1:3000 in 1%
gelatin-PBST for 1 hour at 25°C. The membrane was
washed again in PBST, and chemiluminescent substrate
(SuperSignal, Pierce, Rockford, USA) was applied for visualization of the corresponding bands.
To ascertain equal protein loading, the blot was reprobed
with mouse monoclonal anti-actin antibody (pan, Ab-5;
NeoMarkers, Fremont, CA, 0.5 μg/ml) and developed
with goat anti-mouse IgG and IgM (Jackson Immunoresearch, West Grove, PA) diluted 1:5000 for 1 hour at
25°C.
Band densities were quantified by densitometry using the
Fluorchem digital imaging system (Alpha Innotech Co.,
San Leandro, CA). The resulting crude optical density
(O.D.) was subtracted from the mean of O.D. of the background.
CBB staining
Gels destined to mass spectrometric analysis were stained
with Coomassie Brilliant Blue (CBB) R-250 (Serva, Germany) for vizualization of all separated proteins. After
SDS-PAGE, the gels were incubated at room temperature
in a solution containing CBB (0.25% CBB R-250, 7%
CH3COOH, 50% ethanol) for 1 hour. After incubation
with CBB, the gels were washed in destaining solution
(35% ethanol, 10% CH3COOH) until the background
dissapeared and the separated proteins were clearly and
sharply visible.
Mass spectrometric analysis
The spots of interest were excised from the Coomassie R250- stained SDS-PAGE gel. Destaining, digestion with
trypsin, and preparation of the resulting protein mixtures
for mass spectrometric analysis were performed in accordance with Kovarova et al. [13].
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Mass spectra were collected in the reflection mode in a
matrix-assisted laser desorption/ionization reflection
time-of-flight MALDI-TOF mass spectrometer BIFLEX
(Bruker-Franzen, Bremen, Germany). Analysis based on
peptide mass fingerprinting at ProFound searching was
performed.
Tissue processing and peroxidase immunohistochemistry
Tissue processing and peroxidase immunohistochemistry
was performed as described previously [9], with some
modifications. Briefly, several 10 × 10 × 5 mm blocks of
tissue were collected from different central cotyledons
into cryomold biopsy vinyl specimen molds (Tissue Tek
Cryomold Biopsy, Miles Inc. Division, Elkhart, IN) which
were frozen by floating on liquid nitrogen and stored at 80°C until use. Frozen tissues were sliced into 7 μm serial
sections and placed on a slide. The slides were dried for 16
hours in a hood, fixed for 10 minutes in acetone at room
temperature, and stored at -20°C until the day of immunostaining. Before immunohistochemistry, the slides
were transferred at -20°C into a box with drierite anhydrous calcium sulphate (W.A. Hammond Drierite Co, Ltd,
Xenia, OH) to prevent water condensation during the
equilibration at room temperature, and then incubated
overnight (at 4°C) with non-diluted primary antibody
TRO-tf-01. Control staining consisted of the replacement
of the primary antibody with PBS, pH 7.22. The slides
were then washed three times in PBS and incubated 20
minutes with the peroxidase conjugate swine anti-mouse
IgG (SWAM/Px; Sevapharma, Prague, Czech Republic)
diluted 1:50, washed again three times, and visualized
with 3,3'-diaminobenzidine tetrahydrochloride followed
by a slight hematoxylin counterstain [9].

Evaluation was performed under a Leitz DM RB (Leica
Inc., Wetzlar, Germany) microscope equipped with differential interference contrast and a DEI-470 CCD Video
Camera System (Optronics Engineering, Goleta, CA) with
detail enhancement. The images were captured by a CG-7
color frame grabber (Scion Corporation, Frederick, MD)
supported by Scion Image public software developed at
the National Institutes of Health (Wayne Rasband, NIH,
Bethesda, MD).
For the purpose of density measurement, the slides were
immunostained for TF without hematoxylin counterstain.
Five density measurements (area 100 square pixels) were
performed for each placental sample. The resulting crude
optical density (O.D.; scale 0–255) was subtracted from
the mean of the O.D. background. Such "net O.D." values
were used for statistical analysis.
Statistical analysis
The net O.D. values were subjected to one-way ANOVA
with Tukey-Kramer multiple comparisons post-test using
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the GraphPad InStat version 3.00 for Windows (GraphPad Software, San Diego, California, USA). Statistical significance was set at p < 0.05.

Results
In a further study, we focused on the monoclonal antibody TRO-tf-01, which was found to specifically interact
not only with JAR cells, but also with placenta lysates that
exhibited differences in staining with respect to their origin. This antibody could also be used in immunohistochemical experiments on placenta tissue sections.
Available clinical data of the pregnancies are shown in
Table 1.
Determination of antigen corresponding to MoAb TRO-tf01
In 2-D electrophoresis, we used placenta lysates for antigen characterization (Figure 1). The positive ion mass
spectra were measured in the reflection mode for the analysed proteins. The received values of m/z were used for
protein identification after removing the matrix peaks and
trypsin autoproteolytic peptides. The protein labeled by
TRO-tf-01 was further defined by mass fingerprinting
analysis. The obtained MALDI-MS spectra were interpreted by the ProFound database searching program [14].
The obtained peptides were matched with human transferrin peptide fragments (NP_001054.1, PRO2086, transferrin, Homo sapiens) with the sequence coverage of 31%
and Z-score of 2.31. ProFound calculated the probability
that a candidate in the database search is the protein being
analyzed. As an indicator of the quality of the search
result, a Z-score is estimated. A Z-score of 2.31 corresponds to the 99th percentile of the search in a random
Table 1: Clinical data of the pregnancies.

1
2
3
4
5
6
7
8
9
10
11
12

Age

W

Sex

mpl

m

BP

placenta
type

24
30
20
22
30
32
34
34
27
22
32
39

37,6
40,5
34,0
36,4
39,5
36,6
38,1
36,3
37,3
37,2
39,3
37,2

F
M
F
M
F
M
M
F
F
M
F
F

620
1000
817
526
610
645
815
660
880
650
600
593

3310
5115
2220
2615
2955
2810
3800
2805
3415
3665
3245
3180

136/87
90/53
112/65
111/77
199/85
133/82
117/59
115/71
109/74
141/75
140/41
140/78

N
N
N
DrA
DrA
DrA
GD
GD
GD
PIH
PIH
PIH

NP, normal pregnancies; GD, gestational diabetes during pregnancy;
PIH, pregnancy-induced hypertension during pregnancy; DrA, drugabusing mothers during pregnancy.
w – week of gestation, M – male, F – female, mpl – weight of placenta,
m – weight of newborn, BP – blood pressure
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match population. Thus, mass spectrometric analysis
showed that MoAb TRO-tf-01 is specific to one isoform of
transferrin (TF), a glycoprotein of estimated molecular
weight of 79.3 kDa and pI 6.9. Although MALDI-TOF
analysis revealed more isoforms of transferrin that probably represent various posttranslational modifications of
one protein (Figure 1A), only one isoform was detected
with the TRO-tf-01 antibody (Figure 1B).
Specificity of MoAb TRO-tf-01, immunobiochemistry
The monoclonal antibody TRO-tf-01 selected for the
present study is of the IgG1 isotype, containing kappa
light chains as determined by a mouse monoclonal antibody isotyping kit (IsoStrip, Roche, Indianapolis, USA).

Positive reactions of antibody TRO-tf-01 were gained in
ELISA assay and Western blot analysis using NP-40 and
SDS extracts of JAR cells and placental tissues (Figure 2),
where MoAb labeled a protein of molecular weight ~80
kDa (Figure 1, 2).
According to the observed characteristics, the placenta
samples were subdivided into two groups – normal and
abnormal pregnancy (selected abnormalities – gestational
diabetes, pregnancy induced hypertension, drug abusers).
In biochemical experiments, expression differences of
transferrin among placental samples were observed. In
general, we noticed stronger reactions with TRO-tf-01 in
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placental samples originating from abnormal pregnancies
(Figure 2, lane 1, 2, 3, 5) as opposed to the normal ones
(Figure 2, lane 4).
Quantitative evaluation of TRO-tf-01 has shown a marked
difference between net O.D. of the expression in the placentae of normal pregnancies and the placentae of mothers with gestational diabetes, pregnancy-induced
hypertension, and drug abusers (Figure 2, bottom).
Immunohistochemistry
Consistent strong expression of TF was found in all evaluated placentae in extravillous cytotrophoblast in the placental basal plate, fetal membranes (arrowhead, Figure
3A), and in amniotic epithelium (black arrowhead, Figure
3A).

However, differences in TF expression were detected
between the placentae from normal and abnormal pregnancies in villous syncytiotrophoblast, which is in direct
contact with maternal blood. In placentae from normal
pregnancies, the expression of TF in syncytium was low
(Figure 3C). Very strong expression was observed in syncytium of the placentae of mothers with gestational diabetes (Figure 3D), pregnancy-induced hypertension (Figure
3E), and drug abusers (Figure 3F).

Figure 1lysate stained with CBB after 2D-SDS PAGE (A) and immunodetection with TRO-tf-01 antibody (B)
Placenta
Placenta lysate stained with CBB after 2D-SDS PAGE (A) and immunodetection with TRO-tf-01 antibody (B).
A 13 cm Immobiline DryStrip of pH range 4–7 was used for the separation of the total protein lysate according to pI, in the
second dimension, 10% polyacrylamide slab gel (SDS) was used. After immunoblotting with MoAb TRO-tf-01, only one isoform
(arrow) of transferrins (underlined) was labeled (B). Detected antigen was identified by MALDI-TOF analysis as human transferrin (TF, sequence coverage of 31%, Z-score of 2.31). Molecular weight is shown on the left.
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TRO-tf-01
Western
normal
Figure
and
2 blot
selected
analysisabnormal
of chorionic
pregnancies
villi of the
with
placentae
antibody
from
Western blot analysis of chorionic villi of the placentae from normal and selected abnormal pregnancies
with antibody TRO-tf-01. Actin is used as a control for
protein loading; lysates (NP-40) were loaded on 10% acrylamide gel (SDS, reducing conditions). Quantitative evaluation
of TRO-tf-01 expression (O.D.) in the placentae is placed at
the bottom. Placentae of mothers with 1 – drug abuse during
pregnancy (DrA), 2 – pregnancy-induced hypertension
together with gestational diabetes (PIH+GD), 3 – gestational
diabetes (GD), 4 – normal pregnancy, 5 – pregnancy-induced
hypertension (PIH).

Quantitative evaluation of TRO-tf-01 immunoreactivity is
presented in Figure 4. Statistical analysis has shown highly
significant differences (p < 0.001) between the net O.D. of
placentae from normal pregnancies and the placentae of
mothers with gestational diabetes, pregnancy-induced
hypertension, and drug abusers.

Discussion
During implantation, the embryo shows an invasive phenotype and further, it eludes the immune system [15].
Thus, critical factors of maternal-fetal interaction seem to
be of an immunological character [16]. Some of the
immunological responses are of general importance;
however, the majority of them are specific for maternalfetal interactions [17,18]. It is obvious that the study of
implantation and placenta formation is complex as many
different cells and molecules participate in these processes. We can suppose that proteins, which are normally
found at the maternal-fetal interface, are also important
for successful embryo implantation, and their altered
expression may therefore be connected with placental
abnormalities. One of these significant proteins may be
transferrin (TF).
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As placental cells produce TF, it is supposed to function in
transport or regulation of iron passage across this barrier
[6]. Its defficiency (dysbalance) can result in some disorders influencing fetus development. There are various isoforms of transferrins in the placenta tissue ensuring iron
supplementation of the fetus. It may be suggested that the
increase of TF variants is correlated to an increase of iron
transport [19]. According to the databases it is evident that
the family of TFs exibits a great sequence variability with
many aminoacid substitutions in different TF isoforms
leading to a change of epitope properties. Moreover, in
accordance with our findings, post-translational modifications of the TF epitopes (e.g. glycosylation) that differ in
various cells and tissues were described [19]. All these variants can also change the TFs' functional properties to
make the system of iron exchange even more effective.
One of such variants might be the isoform detected by our
antibody TRO-tf-01. According to the observations in placenta lysate, our MoAb TRO-tf-01 interacts with only one
of the TFs (Figure 1) carrying a particular epitope which is
not detectable in all TF forms. However, the phenomenon
underlying this difference remains unclear for the present
and needs to be elucidated.
A newly prepared MoAb against one isoform of TF reacted
with JAR cells and placenta samples. In Western blot analysis, we found stronger reactions of all samples originating from placentae of selected abnormalities, when
compared to the normal ones. However, these results
themselves do not describe the placental status in the
sense of abnormality, as various particular regions of placental tissue vary in the levels of TF expression. Therefore,
these differences do not necessarily correspond with the
placental status.
Thus, we used sections of well-characterized placentae for
histological evaluation of TF expression patterns. Low
expression of TF in the syncytiotrophoblast of the placentae from normal term pregnancies indicates existing saturation of fetal demands. Increased TF expression in the
placentae from pregnancies of selected abnormalities may
indicate an increased need for the TF function to meet the
fetal iron needs. Hence, the enhanced expression of TF in
the villous syncytiotrophoblast in selected abnormal pregnancy placentae may indicate an activation of an adaptive
placental mechanism to satisfy the altered fetal demands
for iron. In summary, we speculate that a strong expression of TF in the syncytiotrophoblast of selected abnormal
pregnancy placentae is one of the responses to developing
or existing fetal stress.
Morris Buus and Boockfor [6] described TF expression by
both differentiated and non-differentiated placental cells,
which strengthens the possibility that placental TF may be
central to the passage of iron from the mother to the fetus
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Immunoreactivity
Figure 3
of TRO-tf-01 in chorionic villi of placentae from normal and selected abnormal pregnancies
Immunoreactivity of TRO-tf-01 in chorionic villi of placentae from normal and selected abnormal pregnancies.
A) Fetal membranes show very strong expression of transferrin by amniotic epithelium (full arrowhead) and on extravillous
cytotrophoblast cells (arrowhead). B) Control experiment without primary antibody shows no transferrin staining in the syncytium of normal term placenta. C) Very low expression of transferrin in the syncytium of normal term placenta. D) Placenta of
mother with gestational diabetes shows strong villous expression of transferrin. E) Placenta of mother with pregnancy-induced
hypertension shows strong expression of transferrin in villous syncytium. F) Placenta of drug-abuse mother during pregnancy;
the transferrin expression is very strong. Hematoxylin counterstained the nuclei.
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Figure 4samples
Quantitative
placental
evaluation of TRO-tf-01 immunoreactivity in
Quantitative evaluation of TRO-tf-01 immunoreactivity in placental samples. Each column represents mean
(± SE) from fifteen net optical densities (Net O.D.) measured
in three different placentae. NP, normal pregnancies; GD,
gestational diabetes during pregnancy; PIH, pregnancyinduced hypertension during pregnancy; DrA, drug-abusing
mothers during pregnancy. Statistical analysis has shown
highly significant differences (p < 0.001) between normal (a)
and each of the selected abnormal pregnancy types (b).

during development. Moreover, according to Verrijt et al.
[4], TF synthesis is not an exclusive property of the differentiated syncytiotrophoblast cells, suggesting that the
state of cell differentiation might be just a determinant
factor of the TF expression level. However, we observed
consistent cytotrophoblast expression of TF in all used
placenta samples, whereas the syncytiotrophoblast TF
expression varied among various samples. As cytotrophoblast represents a precursor of syncytiotrophoblast
and differentiates into syncytium during placenta formation, its function is important during implantation and
early placentation. Therefore, the presence of TF in the
extravillous cytotrophoblast suggests its possible involvement in such events.
Interestingly, strong expression of TF was also found in
amniotic epithelium [4]. However its importance here
remains unclear. Although there are reports showing evidence of TF production in the placenta [4,6], it does not
necessarily mean that the increase in TF expression in the
placentae after an abnormal pregnancy course is due to
the increased production of TF in the cell or that TF in the
cell is highly active. Another possible explanation is that
the metabolism of TF in the syncytiotrophoblasts might
be prevented. The explication can be connected with the
presence of transferrin receptor (TfR, a transmembrane
protein mediating the cellular iron uptake by binding and
internalization of diferric transferrin) and its function that
can influence the amount of TF in the placenta [20,21].
Several iron transporters and regulators were character-
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ized recently. Interestingly, these iron transporters localized in placental trophoblast cells, mainly in recycling
endosomes, were found to interact. It was also suggested
that the level of intracellular iron may regulate both TfR
expression and TfR trafficking/transcytosis in polarized
cells [22]. In cultured cytotrophoblasts, TfR levels increase
in cells cultured in iron-poor medium, indicating that
iron has an effect on the TfR synthesis/breakdown ratio.
These cultured trophoblasts regulate iron uptake by variation of the number of surface TfRs via changes in total
TfRs and their redistribution in the membrane [23]. Also,
in vivo the placenta minimizes the effect of the deficiency
by up-regulating the proteins involved in Fe transfer. For
example, TfR levels increase inversely to maternal Fe levels
[24], which was described to occur in diabetic pregnancies
that are complicated by low fetal iron stores. There the
expression of TfR is increased, suggesting the regulation of
placental iron transport by fetoplacental iron status [25].
Iron deficiency during pregnancy is common and has serious effects such as fetal growth retardation and cardiovascular problems in the adult offspring. Supplementation
with iron is generally recommended during pregnancy to
meet the iron needs of both mother and fetus. However,
iron supplements and increased iron stores have recently
been linked to maternal complications (e. g., gestational
diabetes) and increased oxidative stress during pregnancy
[7]. Consequently, while iron supplementation may
improve pregnancy outcome when the mother is irondeficient, it is also possible that prophylactic supplementation may increase the risk when the mother does not
have iron deficiency or iron deficiency anemia [7].
The relation between drug abuse and iron metabolism is
known. For instance, an increased level of iron also connected with pathological events such as alcoholic liver disease was described [26]. Even mild to moderate alcohol
consumption has been shown to increase the prevalence
of iron overload. Both iron and alcohol individually cause
oxidative stress and lipid peroxidation, which culminates
in liver injury. Despite these observations, the underlying
mechanisms of iron accumulation remain unclear [26].
It is evident that a certain level of iron is important for the
metabolism and proper cell proliferation and its dysbalance may be connected with various abnormal events in
the organism. The importance of TF in trophoblast differentiation is well known; however, our present results indicate the possible involvement of a higher TF level,
accompanying selected abnormal pregnancies, at the
maternal-fetal interface.
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